206
Participants
Start Date
December 31, 2007
Primary Completion Date
June 30, 2010
Study Completion Date
August 31, 2015
ABR-215050, tasquinimod
Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
Placebo
Identical appearing gelatin capsules containing placebo
Beth Israel Medical Center, New York
University Urological Associates, New York
Staten Island Urological Research, PC, Staten Island
Community Care Physicians, PC / The Urological Institute of Northeastern New York, Albany
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Physicians, Department of Urology, Pittsburgh
Urologic Consultants of SE PA, Bala-Cynwyd
Center for Urologic Care of the Main Line, Bryn Mawr
Johns Hopkins, Baltimore
Virginia Oncology Associates, Norfolk
Virginia Oncology Associates, Newport News
Virginia Oncology Associates, Hampton
Wake Urological Associates, Raleigh
Duke University Medical Center, Durham
Peachtree Hematology-Oncology Consultants, Atlanta
Southeastern Resarch Group, Inc., Tallahassee
Diagnostic Professionals, Inc, Plantation
Midwest Urology/RMD Clinical Research Institute, Melrose Park
Evanston Northwestern Healthcare, Evanston
University of Chicago, Chicago
Galesburg Cottage Hospital, Galesburg
Medical and Surgical Specialists, Galesburg
OSF St Mary Medical Center, Galesburg
M.D. Anderson Cancer Center, Houston
Porter Adventist Hospital, Denver
Urology Associates, PC, Denver
Idaho Urologic Institute, PA, Meridian
St. Alphonsus Regional Medical Center, Boise
North Idaho Urology, Coeur d'Alene
North Idaho Urology, Sandpoint
Urology Group of New Mexico, Albuquerque
Pacific Clinical Center, Beverly Hills
Pacific Clinical Research, Santa Monica
Agajanian Institute of Oncology and Hematology, Whittier
Southern California Permanente Medical Group, Bellflower
Southern California Permanente Medical Group, Baldwin Park
South County Hematology/Oncology, Chula Vista
Cancer Center Oncology Medical Group, La Mesa
North County Oncology Medical Clinic, Inc., Oceanside
Urological Physicians of San Diego, Inc., San Diego
Southern California Permanente Medical Group, San Diego
Medical Oncology Associates - SD, San Diego
Sharp Memorial Hospital Investigational Pharmacy, San Diego
Sharp Rees-Stealy, San Diego
Southern California Permanente Medical Group, Fontana
San Bernardino Urological Associates, San Bernardino
Southern California Permanente Medical Group, Irvine
Southern California Permanente Medical Group, Anaheim
Seattle Urology Research Center, Burien
Roger D. Fincher, M.D., P.S., Spokane
Alaska Clinical Research Center LLC, Anchorage
AdvanceMed Research, Lawrenceville
Urological Associates of Lancaster, Lancaster
Vanderbilt University Medical Center, Nashville
Andreou Research, Surrey
Surrey Memorial Hospital, Surrey
Guelph General Hospital, Guelph
Guelph Nuclear Imaging, Guelph
Guelph Urology Associates, Guelph
Office of Dr. Bernard Goldfarb, North Bay
2150935 Ontario Inc., Owen Sound
3030 Lawrence Ave East, Scarborough Village
Institute of Clinical Sciences, Dept. of Urology / Sahlgrenska University Hospital, Gothenburg
University Hospital, Department of Urology, Malmo
Dept. of Urology, Akademiska Sjukhuset, Uppsala
Lead Sponsor
Active Biotech AB
INDUSTRY